Nyra health has raised €20m in a Series A round to expand its AI-based neurorehab platform across Europe and the US.
The Vienna-based company said it will use the funding to expand its technology platform in the DACH region, accelerate its US expansion and pursue its aim of setting a new standard for data-driven neurorehabilitation.
Moritz Schöllauf, chief executive and co-founder of nyra health, said: “From the outset, our goal was to make our services widely available to those affected.
“Everyone who needs therapy after a stroke or other neurological disease should have access to effective, individualised care, regardless of where they live or how well their own healthcare system is set up.
“With this round of financing, we are taking another step in this direction.”
Neurological diseases such as stroke, dementia and traumatic brain injury account for €65bn in annual costs in Germany alone, largely because therapy often stops or drops sharply in intensity after patients leave hospital. This can lead to gaps in care and higher long-term costs due to avoidable complications.
Nyra health said its platform addresses this by enabling continuous therapy from inpatient treatment through to long-term outpatient care.
Its AI-based platform, myReha, is now used in more than 100 neurological clinics, where it supports speech, cognition, fine motor skills and daily living activities through AI-assisted exercises with real-time feedback.
Therapy can continue after discharge, with nyra health recognised as a digital application within Germany’s pension insurance system, described as Europe’s largest rehabilitation provider.
The company said 28 statutory and private health insurers in Germany already reimburse myReha automatically, giving more than 40m insured individuals access to structured, AI-based home therapy.
At the centre of the platform is myReha, an MDR Class IIa certified medical device.
It uses multimodal AI to analyse speech, reaction times, error patterns and training dynamics, allowing therapy to adapt automatically to performance level, fatigue and progress.
Nyra health said the effectiveness of myReha has been clinically demonstrated.
In a randomised controlled study, patients using the platform alongside standard therapy showed significantly greater improvements in cognitive and language functions.
The system is supported by nyra insights, which allows therapists to monitor progress in real time, adjust programmes and generate documentation automatically.
An AI-supported Content Studio also creates personalised therapy content based on individual performance data.
The funding round was led by Armira Growth.
Existing investors Wellington Partners, Crane Venture Partners, which oversees MassMutual Ventures’ investments, and EVER Pharma also participated.
Christian Figge, managing partner at Armira Growth, said: “Neurological rehabilitation can be made significantly more effective through digital solutions, especially in the area of speech ability.
“nyra health is considered a true category creator with a proprietary AI-based solution that seamlessly connects the entire care chain, from inpatient therapy to outpatient aftercare to home use, for the first time.
“We were also particularly impressed by the strong clinical evidence and deep integration into the German standard of care, which already gives nyra health access to over 40 million insured individuals.
“On this basis, the company is ideally positioned to define the market for digital neurorehabilitation internationally as well.”
Epilepsy drug firm secures US$2.4m grants
